Welcome to our dedicated page for Boston Scien Cp SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Boston Scientific Corporation (NYSE: BSX) files a broad range of reports and disclosures with the U.S. Securities and Exchange Commission, providing detailed insight into its operations as a global medical technology company. These SEC filings cover topics such as financial performance, material acquisitions, executive compensation programs, governance changes and risk factors relevant to the business.
On this page, you can review Boston Scientific’s current reports on Form 8-K, which the company uses to announce material events. Recent 8-K filings describe the definitive agreement to acquire Penumbra, Inc., including references to a joint press release and investor presentation, as well as the adoption of a 2026 annual bonus plan and performance share programs tied to metrics like global sales, adjusted earnings per share, relative total shareholder return and organic net sales growth. Other 8-Ks report quarterly financial results, director retirement plans and changes in senior leadership roles.
In addition to 8-Ks, Boston Scientific’s annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system) include consolidated financial statements, segment and geographic net sales data, discussions of MedSurg and Cardiovascular businesses, and extensive risk factor sections. These filings also explain the company’s use of non-GAAP financial measures such as operational and organic net sales growth and adjusted earnings per share, with reconciliations to GAAP figures.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on acquisitions, compensation plans, performance metrics and risk disclosures. Real-time updates from EDGAR ensure that new Boston Scientific filings, including Forms 10-K, 10-Q and 4 (insider transaction reports), are added as they become available, while AI-generated explanations assist in interpreting complex financial and legal language.
Penumbra, Inc. has agreed to be acquired by Boston Scientific Corporation in a cash-and-stock merger. Under the Agreement and Plan of Merger, each issued and outstanding Penumbra share (other than excluded shares) will be converted into the right to receive either $374.00 in cash or 3.8721 Boston Scientific shares, subject to a proration mechanism that allocates 73.26% of outstanding Penumbra shares to cash consideration and 26.74% to stock consideration.
The Special Meeting of Penumbra stockholders is scheduled for May 6, 2026 to vote on adoption of the merger agreement. Boston Scientific is expected to issue approximately 43,866,267 shares in the transaction, with former Penumbra stockholders holding about 2.87% of Boston Scientific post-close, based on figures as of March 27, 2026.
Boston Scientific Corporation is registering shares in connection with its proposed acquisition of Penumbra, Inc. under an Amendment No. 1 to a Form S-4. Under the Agreement and Plan of Merger dated January 14, 2026, Penumbra will merge into a Boston Scientific subsidiary and Penumbra shareholders will receive, per Penumbra share, either $374.00 in cash or 3.8721 Boston Scientific Shares, subject to a proration mechanism that allocates 73.26% of Penumbra shares to cash and 26.74% to stock.
The proxy/prospectus sets the Special Meeting for May 6, 2026, describes election procedures and deadlines, treatment of equity awards (including a conversion formula and an Equity Award Stock Consideration of 1.0353 shares for certain awards), regulatory and closing conditions, appraisal rights, and termination fees of $525 million (to Boston Scientific in certain cases) and $900 million (to Penumbra in certain cases). Based on shares outstanding as of March 27, 2026, Boston Scientific expects to issue approximately 43,866,267 shares, with former Penumbra shareholders holding about 2.87% of Boston Scientific post-closing.
Boston Scientific filed an 8-K to share landmark clinical data for two cardiovascular therapies. The HI-PEITHO randomized trial in 544 patients with intermediate-risk pulmonary embolism showed the EKOS endovascular system plus anticoagulation was superior to anticoagulation alone on a composite endpoint (4.0% vs. 10.3%; 61% relative reduction), without intracranial bleeding through 30 days and with shorter hospital stays.
The CHAMPION-AF trial in 3,000 patients with non-valvular atrial fibrillation found the WATCHMAN FLX left atrial appendage closure device met all primary and secondary safety and efficacy endpoints versus leading blood thinners over 36 months, delivering markedly lower non-procedural bleeding (10.9% vs. 19.0%) and similar protection from stroke and cardiovascular death, with a 99% procedural success rate.
Boston Scientific Corp ownership disclosure: The Vanguard Group filed an amendment reporting that, after an internal realignment, it and certain subsidiaries will report beneficial ownership separately. The amendment states amount beneficially owned: 0 and percent of class: 0% as of the filing. The filing explains the disaggregation follows SEC Release No. 34-39538 and that subsidiaries pursue prior investment strategies.
Boston Scientific Corporation is asking stockholders to vote at a virtual 2026 Annual Meeting on April 30, 2026 at 8:00 a.m. Eastern Time. Holders of common stock at the close of business on March 6, 2026, when 1,486,175,167 shares were outstanding, may vote.
Stockholders are asked to elect ten directors, approve on an advisory basis the compensation of named executive officers, and ratify Ernst & Young LLP as independent auditor for the 2026 fiscal year. The Board recommends voting FOR all three items.
The agenda includes governance and capital proposals: amending the Employee Stock Purchase Plan to increase shares reserved; removing supermajority voting provisions; adding Delaware-permitted officer exculpation; and allowing stockholders holding 25% of common stock to call a special meeting. The Board supports these four proposals and recommends AGAINST a separate stockholder proposal titled “Give Shareholders the Ability to Call for a Special Shareholder Meeting.”
Boston Scientific Corporation is asking shareholders to vote at its virtual Annual Meeting on April 30, 2026 (virtual webcast at www.virtualshareholdermeeting.com/BSX2026) for holders of record as of March 6, 2026. The Board recommends FOR proposals 1–7 (including director elections, say‑on‑pay, accountant ratification, ESPP increase, and amendments to the Certificate of Incorporation and By‑Laws) and AGAINST the stockholder proposal to allow special meetings. The proxy materials describe Board refreshment: Cathy R. Smith and Christophe P. Weber joined the Board in February 2026, and John E. Sununu and Yoshiaki Fujimori will not stand for re‑election. Voting instructions, quorum rules, and voting methods (internet, phone, mail, virtual attendance) are provided in the proxy materials.
Boston Scientific director Cheryl Pegus reported an equity award in the form of deferred stock units. On March 2, 2026, she acquired 24 deferred stock units at a stated price of $0.00 per unit, reflecting $1,845.25 of compensation based on the common stock’s closing price that day.
Each deferred stock unit represents a commitment by Boston Scientific to issue one share of common stock in the future. These units were granted in lieu of 50% of her yearly cash compensation, vest in full at the next annual stockholder meeting, and the underlying shares will be delivered after she leaves the Board under the company’s non-employee director deferred compensation plan. Following this grant, her reported direct holdings total 5,917 deferred stock units.
Morano Susan E reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Susan E. Morano received an equity grant of 24 shares of common stock on March 2, 2026, at no cash cost to her. The award is restricted stock granted in lieu of 50% of her cash compensation, valued at $1,845.25 based on the closing share price on the grant date, and will vest in full at the next annual meeting of stockholders. Following this grant, she directly holds 6,663 Boston Scientific shares.
Boston Scientific director Christophe Pierre Weber reported receiving two restricted stock grants as a non-employee director. He acquired 556 shares of common stock as an initial equity award with an approximate value of $42,419.50, prorated under the company’s non-employee director compensation program.
Weber also received 323 restricted shares in lieu of 100% of his prorated yearly cash retainer, with an approximate value of $24,662.50. Both grants were based on the closing stock price on the grant date and are scheduled to vest in full at the company’s 2026 annual meeting of stockholders.